- Home
- STRW vs DMAC Comparison
STRW vs DMAC Comparison
Compare STRW & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRW
- DMAC
- Stock Information
- Founded
- STRW 2015
- DMAC 2000
- Country
- STRW United States
- DMAC United States
- Employees
- STRW N/A
- DMAC N/A
- Industry
- STRW Real Estate Investment Trusts
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- STRW Real Estate
- DMAC Health Care
- Exchange
- STRW Nasdaq
- DMAC Nasdaq
- Market Cap
- STRW 133.6M
- DMAC 158.1M
- IPO Year
- STRW N/A
- DMAC N/A
- Fundamental
- Price
- STRW $10.20
- DMAC $4.11
- Analyst Decision
- STRW Strong Buy
- DMAC Strong Buy
- Analyst Count
- STRW 4
- DMAC 2
- Target Price
- STRW $13.83
- DMAC $8.00
- AVG Volume (30 Days)
- STRW 50.7K
- DMAC 102.4K
- Earning Date
- STRW 05-09-2025
- DMAC 05-13-2025
- Dividend Yield
- STRW 5.49%
- DMAC N/A
- EPS Growth
- STRW 34.22
- DMAC N/A
- EPS
- STRW 0.58
- DMAC N/A
- Revenue
- STRW $126,557,000.00
- DMAC N/A
- Revenue This Year
- STRW $15.21
- DMAC N/A
- Revenue Next Year
- STRW $2.21
- DMAC N/A
- P/E Ratio
- STRW $17.69
- DMAC N/A
- Revenue Growth
- STRW 22.41
- DMAC N/A
- 52 Week Low
- STRW $8.70
- DMAC $2.14
- 52 Week High
- STRW $12.90
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- STRW 46.67
- DMAC 50.90
- Support Level
- STRW $9.46
- DMAC $3.92
- Resistance Level
- STRW $10.75
- DMAC $4.33
- Average True Range (ATR)
- STRW 0.66
- DMAC 0.29
- MACD
- STRW 0.03
- DMAC 0.02
- Stochastic Oscillator
- STRW 50.79
- DMAC 56.79
About STRW Strawberry Fields REIT Inc.
Strawberry Fields REIT Inc is a self-managed and self-administered company that specializes in the acquisition, ownership and triple-net leasing of skilled nursing facilities and other post-acute healthcare properties.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.